



## **PHARMACOGENOMIC SCREENING “CRITICAL FOR OUR NATION”**

EMBARGOED UNTIL 12:01am Monday 14 November 2022

AUSTRALIA must “expand the implementation of pharmacogenomic screening to elevate the quality of care we offer to patients, on par with or better than international standards”, according to the authors of a Perspective published today by the *Medical Journal of Australia*.

“Pharmacogenomics is the genomic profiling of patients for genetic variants that clinically modify the tolerability and desired effect of specific medications,” wrote the authors, led by Dr Cassandra White, a medical oncologist at Maitland Hospital and the University of Newcastle.

“Patients who carry functional gene variants may have increased or decreased capacity to metabolise medications upon exposure. Some genetic variants have an impact on multiple medications across different drug classes.

“Patients who poorly metabolise medications face toxicities ranging from moderate to severe, requiring hospitalisation or intensive care unit admission and even resulting in death,” wrote White and colleagues.

“Testing for genomic variants implicated in the tolerability of select medications can help us to predict a patient’s metabolic response and adjust medications accordingly, allowing for individualised prescribing.”

Internationally, one gene-drug pair has gained attention – the introduction of upfront dihydropyrimidine dehydrogenase (DPYD) genotyping in patients intended to receive fluoropyrimidine chemotherapy (5-fluorouracil and capecitabine).

“Globally, more than 2 million cancer patients receive fluoropyrimidine per annum, including approximately 10 000 patients in Australia,” wrote White and colleagues.

“Serious toxicities resulting in hospitalisation and occasional intensive care admission occur in approximately 30% of treated cases. Up to 1% of patients die from fluoropyrimidine chemotherapy-related toxicity. Four DPYD variants are found in approximately 3-8% of the European population and lead to a significant increase in the relative risk of developing serious adverse events including diarrhoea, mucositis, myelosuppression, and hand-foot syndrome.

“There is evidence to support reducing fluoropyrimidine dosing in patients carrying significant DPYD gene variants, leading to decreased toxicity without compromising treatment response,” they wrote.

Despite that evidence, “to date, pre-emptive DPYD screening has not been adopted systematically in Australia”.

Cost is one reason – “Medicare rebate currently only applies for thiopurine methyltransferase (TPMT) and human leukocyte antigen (HLA-B\*57:01) genotyping for eligible patients; all others are conducted at patient expense,” wrote White and colleagues.

“Currently, patients can obtain pharmacogenomic testing services through their physician or pharmacist, or directly through direct-to-consumer services. As a result, it is difficult to capture the extent of uptake of pharmacogenomic testing in Australia.

“This raises several concerns, predominantly the lack of standardisation of testing, protection of patients’ genomic information, and the interpretation and use of genomic results outside of the health care setting.”

White and colleagues pointed out the cost-effectiveness of pharmacogenomics-guided prescribing decisions over a 5-year projection period, including a predicted saving of \$2.5-6.2 billion.

“Despite the knowledge that a critical DPYD variant can lead to lethal toxicity on exposure to fluoropyrimidine chemotherapies, there is still no nationally funded or endorsed support to pre-emptively identify these individuals,” they wrote.

“There are already robust fluoropyrimidine dose guidelines and infrastructure to genotype patients through commercial laboratories. We have feasibility data confirming a median turnaround time of 7 days, although this is yet to be evaluated on a large scale and within public hospital service laboratories.

“Additionally, although we have some understanding of the international economic impact of DPYD genotyping, an Australian-specific cost-effectiveness analysis must be conducted to confirm financial viability.

“Streamlining pharmacogenomic screening through clinical stakeholders would additionally serve to improve the appropriate dissemination and interpretation of results while protecting genomic information and ensuring that prescribing guidelines are followed safely and appropriately.

“Providing Australia-wide equitable access to pharmacogenomic services is a major challenge, but a critical one for our nation.

“DPYD genotyping could readily serve as a prototype for the streamlined expansion of pharmacogenomic screening for utilisation across various drug classes prescribed within various medical disciplines.”

All MJA media releases are open access and can be found at: <https://www.mja.com.au/journal/media>

**Please remember to credit *The MJA*.**

The *Medical Journal of Australia* is a publication of the Australian Medical Association.

---

*The statements or opinions that are expressed in the MJA reflect the views of the authors and do not represent the official policy of the AMA or the MJA unless that is so stated.*

**CONTACTS:**

Dr Cassandra White  
Medical Oncologist, Maitland Hospital  
Hunter Medical Research Institute  
Ph: 0422 497 110 or 02 4087 1782  
Email: [Cassandra.White10@uon.edu.au](mailto:Cassandra.White10@uon.edu.au)

Emma Castle  
Media/Communications HMRI  
Phone: 02 4042 0000